Salix Pharmaceuticals Ltd (SLXP.OQ)
60.39USD
24 May 2013
$0.70 (+1.17%)
$59.69
$59.58
$60.84
$59.50
142,825
166,022
$60.84
$37.55
SLXP.OQ
About
Overall
| Beta: | 0.66 |
| Market Cap (Mil.): | $3,659.28 |
| Shares Outstanding (Mil.): | 61.30 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| SLXP.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 48.96 | 34.14 | 34.28 |
| EPS (TTM): | 1.22 | -- | -- |
| ROI: | 4.81 | 19.49 | 18.85 |
| ROE: | 14.45 | 20.26 | 19.72 |
FDA approves Salix's diarrhea drug for HIV/AIDS patients
- U.S. health regulators approved Salix Pharmaceuticals Ltd's drug to treat diarrhea in HIV/AIDS patients on antiretroviral therapy, a combination of medicines used to treat HIV infection.
FDA approves Salix's diarrhea drug for HIV/AIDS patients
Dec 31 - U.S. health regulators approved Salix Pharmaceuticals Ltd's drug to treat diarrhea in HIV/AIDS patients on antiretroviral therapy, a combination of medicines used to treat HIV infection.
Competitors
| Price | Change | |
|---|---|---|
| Takeda Pharmaceutical Company Limited (4502.T) | ¥4,745 | -55.00 |
| Ranbaxy Laboratories Limited (RANB.NS) | Rs389.70 | -4.60 |
| Nestle SA (NESN.VX) | CHF65.70 | -0.05 |
| Pfizer Inc. (PFE.N) | $29.04 | -0.07 |
| Abbott Laboratories (ABT.N) | $37.76 | +0.28 |
| Bayer AG (BAYGn.DE) | €84.46 | +0.55 |
| Bayer AG (BAYE.F) | -- | -- |
| GlaxoSmithKline plc (GSK.L) | 1,749.50p | +7.50 |
| Medtronic, Inc. (MDT.N) | $51.33 | -0.13 |
| Shire PLC (SHP.L) | 2,168.00p | +34.00 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Jefferson Research
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
